Ventana PD-L1 (SP142) Assay

被引：0

作者：

McGill, Rachel ^{[1
]}

Michail, Ramez ^{[1
]}

Miller, Brianne ^{[1
]}

Milton, Erica ^{[1
]}

Musyoka, Agnes ^{[1
]}

Musyoka, Rhoda ^{[1
]}

O'Conner, Jada ^{[1
]}

Ogunnaike, Morenike ^{[1
]}

Omeke, Soteria ^{[1
]}

Franklin, Gallop ^{[1
]}

Honeywell, Marlon S. ^{[1
]}

机构：

[1] Florida A&M Univ, Coll Pharm & Pharmaceut Sci, Inst Publ Hlth, Tallahassee, FL 32307 USA

来源：

US PHARMACIST | 2022年 / 47卷 / 10期

关键词：

D O I：

暂无

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

引用

页码：42 / 44

页数：3

共 50 条

[1] Study on the heterogeneity of expression of PD-L1 (Ventana SP142) in breast cancer in space and time
He, J.
Liu, Y.
VIRCHOWS ARCHIV, 2021, 479 (SUPPL 1) : S70 - S70
[2] Development of a PD-L1 Complementary Diagnostic Immunohistochemistry Assay (SP142) for Atezolizumab
Vennapusa, Bharathi
Baker, Brian
Kowanetz, Marcin
Boone, Jennifer
Menzl, Ina
Bruey, Jean-Marie
Fine, Gregg
Mariathasan, Sanjeev
McCaffery, Ian
Mocci, Simonetta
Rost, Sandra
Smith, Dustin
Dennis, Eslie
Tang, Szu-Yu
Damadzadeh, Bita
Walker, Espen
Hegde, Priti S.
Williams, J. Andrew
Koeppen, Hartmut
Boyd, Zachary
APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY, 2019, 27 (02) : 92 - 100
[3] Development of a PD-L1 companion diagnostic IHC assay (SP142) for atezolizumab
Boyd, Zachary S.
Smith, Dustin
Baker, Brian
Vennapusa, Bharathi
Koeppen, Hartmut
Kowanetz, Marcin
Mariathasan, Sanjeev
Bruey, Jean-Marie
Mackey, Howard
Fine, Gregg
Mocci, Simonetta
Hegde, Priti
Williams, J. Andrew
McCaffery, Ian
CANCER IMMUNOLOGY RESEARCH, 2016, 4 (01)
[4] PD-L1 Expression in Metaplastic Breast Carcinoma Using the PD-L1 SP142 Assay and Concordance Among PD-L1 Immunohistochemical Assays
Grabenstetter, Anne
Jungbluth, Achim A.
Frosina, Denise
Hoda, Raza
Dos Anjos, Carlos H.
Patil, Sujata
Sevilimedu, Varadan
Weigelt, Britta
Reis-Filho, Jorge S.
Zhang, Hong
Traina, Tiffany
Robson, Mark E.
Brogi, Edi
Wen, Hannah Y.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2021, 45 (09) : 1274 - 1281
[5] New Approach in the Interpretation of Complex Triple-negative Breast Cancer Immunohistochemistry Specimens Processed With VENTANA PD-L1 (SP142) Assay
Peg, Vicente
Abengozar-Muela, Marta
Acosta, Jesus
Andres, Leire
Garcia-Rojo, Marcial
Hardisson, David
Nicolau, Maria Jesus
Ramos-Oliver, Irma
Rodrigo, Maximiliano
Sanchez-Bernal, Maria Luisa
Sanz, Julian
Garrote, Leia
Ramirez, Ignacio
Rojo, Federico
APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY, 2025, 33 (01) : 15 - 21
[6] PD-L1 expression in muscle invasive urothelial carcinoma: Comparison of SP142 and SP263 assay
Gupta, Gurudutt
Pasricha, Sunil
Kamboj, Meenakshi
Sharma, Anila
Nayana, N. S.
Durga, Garima
Sharma, Anurag
Rawal, Sudhir
Meh, Anurag
INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY, 2022, 65 (04) : 839 - 843
[7] Comparison of SP142 (Ventana) and SP263 (Ventana) assays to test PD-L1 expression in metastatic cancer patients to be treated with immune checkpoint inhibitors.
Oyan, Basak
Sonmez, Ozlem
Yazar, Aziz
Teomet, Mehmet
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[8] The expression of PD-L1 (Ventana SP142) in HER2-positive breast cancer and its relationship with clinicopathological characteristics
Zhang, Ningning
Liu, Yueping
CANCER RESEARCH, 2021, 81 (04)
[9] PD-L1 Expression in Metaplastic Breast Carcinoma (MBC) Using PD-L1 SP142 Assay and Concordance Among PD-L1 Immunohistochemical (IHC) Assays
Grabenstetter, Anne
Jungbluth, Achim
Frosina, Denise
Hoda, Raza
Weigelt, Britta
Reis-Filho, Jorge
Zhang, Hong
Traina, Tiffany
Robson, Mark
Brogi, Edi
Wen, Hannah
LABORATORY INVESTIGATION, 2020, 100 (SUPPL 1) : 159 - 160
[10] PD-L1 Expression in Metaplastic Breast Carcinoma (MBC) Using PD-L1 SP142 Assay and Concordance Among PD-L1 Immunohistochemical (IHC) Assays
Grabenstetter, Anne
Jungbluth, Achim
Frosina, Denise
Hoda, Raza
Weigelt, Britta
Reis-Filho, Jorge
Zhang, Hong
Traina, Tiffany
Robson, Mark
Brogi, Edi
Wen, Hannah
MODERN PATHOLOGY, 2020, 33 (SUPPL 2) : 159 - 160

← 1 2 3 4 5 →